Join to View Full Profile
3333 Burnet Ave# 2010Cincinnati, OH 45229
Phone+1 513-636-4415
Fax+1 513-636-7805
Dr. Minar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Phillip Minar, MD, is a pediatric gastroenterologist based in Cincinnati, OH. He had his education at the Medical College of Wisconsin for both his medical degree and his residency in pediatrics. Dr. Minar then completed a fellowship in pediatric gastroenterology at Cincinnati Children's Hospital Medical Center, where he also currently serves as an Associate Professor of Pediatrics. He concentrates his practice on pediatric inflammatory bowel disease. He has numerous publications to his name in reputable journals, focused on topics such as the impact of inflammatory biomarkers on anti-TNF therapy in pediatric Crohn's disease, and the role of therapeutic drug monitoring in children. Dr. Minar is leading a multicenter clinical trial entitled "Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease (REMODEL-CD)."
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Gastroenterology, 2010 - 2013
Medical College of Wisconsin Affiliated HospitalsResidency, Pediatrics, 2007 - 2010- Medical College of WisconsinClass of 2007
Certifications & Licensure
KY State Medical License 2020 - 2026
OH State Medical License 2010 - 2026
IN State Medical License 2020 - 2025
WI State Medical License 2009 - 2013
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Gastroenterology
Clinical Trials
- Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) Start of enrollment: 2019 Oct 16
- Precise Infliximab Exposure and Pharmacodynamic Control Start of enrollment: 2023 Jul 01
Publications & Presentations
PubMed
- Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease.Jonathan Moses, Jeremy Adler, Shehzad A Saeed, Ann M Firestine, Joseph A Galanko
Inflammatory Bowel Diseases. 2025-07-07 - Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases.Thomas Aviles, Phillip Minar
The American Journal of Gastroenterology. 2025-06-04 - Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthe...Kei Irie, Phillip Minar, Jack Reifenberg, Brendan M Boyle, Joshua D Noe
Therapeutic Drug Monitoring. 2025-06-03
Grant Support
- Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's DiseaseCINCINNATI CHILDRENS HOSP MED CTR2022–2027
- Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's DiseaseNIDDKPresent
- K23- Therapeutic Monitoring and Targeting of Neutrophil Activation in Pediatric IBDNIH NIDDKPresent
- Redefining Deep Remission in Pediatric Crohn's DiseaseNASPGHAN Foundation/CCFAPresent
Professional Memberships
- NASPGHANMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
